Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023

REDWOOD CITY, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced positive final results from the Phase 1 study of briquilimab in combination with fludarabine and low-dose irradiation (Flu/TBI) conditioning in older adults with acute myeloid leukemia (AML) in complete remission (CR) or myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic cell transplant (HCT). The results were presented by Dr. Arpita Gandhi, M.D., M.S., Assistant Professor of Medicine in the Division of Hematology/Medical Oncology at the Oregon Health & Science University School of Medicine during an oral session at the America Society of Hematology (ASH) 2023 Annual Meeting & Exposition, being held December 9-12, 2023 in San Diego, CA and virtually.

Read more at globenewswire.com